Wei Shen Tan

Dr. Wei Shen Tan, MD, PhD, FRCS, is an Assistant Professor of Urology at Yale School of Medicine, specializing in urologic oncology with expertise in bladder, prostate, and kidney cancers. He completed his Society of Urologic Oncology (SUO)-accredited fellowship at the University of Texas MD Anderson Cancer Center and a robotic urology fellowship at University College London Hospital. Dr. Tan is also an Honorary Associate Professor at University College London and a Fellow of the Royal College of Surgeons of England.

Dr. Tan's research focuses on non-muscle-invasive bladder cancer (NMIBC), with particular interests in cancer diagnostics, novel treatments for bladder cancer, biomarker development, characterization of NMIBC, and optimizing perioperative outcomes through enhanced recovery protocols and robotic surgery. His work has resulted in over 100 peer-reviewed publications, with recent research emphasizing bladder-sparing therapies for BCG-unresponsive NMIBC, tumor stage impact on outcomes, and advancements in diagnosis and risk stratification.

His publication trends show a strong focus on bladder cancer management, particularly BCG-unresponsive cases, with significant contributions to international guidelines and multi-institutional studies. Recent articles (2024-2025) predominantly address bladder-sparing therapies versus radical cystectomy, novel intravesical treatments, tumor staging implications, and international consensus recommendations for NMIBC management.

Dr. Tan serves as a co-investigator in major clinical trials including DETECT I & II, HYMN, BOXIT, and HIVEC-II, and is on the editorial boards of the British Journal of Urology International and the Journal of Men's Health. His clinical approach emphasizes personalized care, minimally invasive robotic surgery when appropriate, and transparent communication with patients throughout their cancer journey.